Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

With today’s approval of romosozumab we can now offer patients and clinicians a new medicine that can help drive positive changes in secondary fracture prevention.”. ... The first launches of romosozumab in the European Economic Area (EEA) are

Latest news

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics